Holen Sie sich die Stockscreener-App
33.64
1.29%
-0.44
Vorhandelsmarkt:
33.78
0.14
+0.42%
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
IDEAYA Biosciences submits IND for novel cancer drug IDE574 By Investing.com - Investing.com Australia
Ideaya Biosciences announces IND submission for IDE574 - marketscreener.com
Ideaya Biosciences Announces Ind Submission For Ide574 - TradingView
IDEAYA Biosciences (Nasdaq: IDYA) submits IND for IDE574, a KAT6/7 inhibitor in breast and lung cancer - Stock Titan
Trading the Move, Not the Narrative: (IDYA) Edition - news.stocktradersdaily.com
GSK (GSK) Plans to End Agreement with Ideaya Biosciences - GuruFocus
Can IDEAYA Biosciences Stock Hold Up When Markets Turn? - Trefis
Why IDEAYA Biosciences Shares Are Under Pressure - TipRanks
GlaxoSmithKline to end collaboration with Ideaya Biosciences on two clinical programs - Investing.com Nigeria
IDEAYA Biosciences Shares Climb After FDA Clears Bispecific ADC Candidate - MSN
GSK ends collaboration with IDEAYA for two candidates - Seeking Alpha
IDEAYA Biosciences Receives Termination Notice from GSK - TradingView
Ideaya Biosciences stock hits 52-week high at 36.57 USD By Investing.com - Investing.com Nigeria
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance - Business Wire India
Will IDEAYA Biosciences Inc. (30J) stock profit from automation wave2025 Short Interest & Advanced Swing Trade Entry Plans - Newser
IDE034, a Bispecific ADC Licensed by Biocytogen Pharmaceuticals Co., Ltd to IDEAYA Biosciences, Inc, Receives FDA IND Clearance - marketscreener.com
IDEAYA Biosciences (Nasdaq: IDYA) gets FDA IND for IDE034 Phase 1 solid tumor study - Stock Titan
How big funds are accumulating IDEAYA Biosciences Inc. (30J) stockJuly 2025 Fed Impact & AI Driven Price Forecasts - Newser
Ideaya Biosciences stock hits 52-week high at 36.57 USD - Investing.com
Is IDEAYA Biosciences Inc. (30J) stock a fit for income portfoliosGDP Growth & Weekly Top Gainers Trade List - Newser
Is IDEAYA Biosciences Inc. (30J) stock safe for risk averse investors2025 Performance Recap & AI Powered Buy and Sell Recommendations - Newser
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 52-Week HighTime to Buy? - MarketBeat
Transcript : IDEAYA Biosciences, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 09 - marketscreener.com
Can IDEAYA Biosciences Inc. stock beat market expectations this quarter2025 Top Gainers & High Yield Stock Recommendations - Newser
Can IDEAYA Biosciences Inc. stock beat analyst upgradesWeekly Profit Recap & Reliable Volume Spike Trade Alerts - Newser
Will IDEAYA Biosciences Inc. (30J) stock hit analyst forecastsTrade Ideas & Daily Profit Maximizing Tips - Newser
IDEAYA receives FDA approval to begin IDE034 clinical trial - Yahoo
Is IDEAYA Biosciences Inc. (30J) stock good for wealth creation2025 Big Picture & Technical Buy Zone Confirmation - Newser
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Citi Global Healthcare Conference - marketscreener.com
Ideaya Biosciences, Inc. Announces Ind Clearance for Ide034, A Potential First-In-Class Bispecific B7h3/Ptk7 Top1 Adc Targeting Multiple Solid Tumor Types - marketscreener.com
IDEAYA receives FDA clearance for bispecific cancer drug IDE034 By Investing.com - Investing.com Nigeria
Sector Update: Health Care Stocks Decline Pre-Bell Monday - marketscreener.com
IDEAYA Biosciences stock rises after FDA clearance for bispecific ADC By Investing.com - Investing.com Nigeria
IDEAYA Biosciences stock rises after FDA clearance for bispecific ADC - Investing.com
Ideaya’s IDE-034 gains IND clearance for solid tumors - BioWorld MedTech
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potenti - GuruFocus
IDEAYA Biosciences Gets FDA Clearance to Begin Phase 1 Trial of IDE034 in Early 2026 - marketscreener.com
Ideaya Biosciences announces clearance for IDE034 - marketscreener.com
Ideaya Biosciences Announces Clearance For IDE034 - TradingView
IDEAYA receives FDA clearance for bispecific cancer drug IDE034 - Investing.com
IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types - marketscreener.com
Handelsbanken Fonder AB Has $561,000 Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
A Closer Look at IDEAYA Biosciences (IDYA) Valuation as Investor Optimism Builds - Yahoo Finance
IDEAYA Biosciences (IDYA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
SG Americas Securities LLC Makes New $423,000 Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
(IDYA) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus
Ideaya Biosciences announces inducement grants under Nasdaq listing rule - TipRanks
Intech Investment Management LLC Sells 20,390 Shares of IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences (NASDAQ: IDYA) issues 17,600 inducement stock options at $35.88 - Stock Titan
IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events - Sahm
Geode Capital Management LLC Grows Stock Holdings in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
How sustainable is IDEAYA Biosciences Inc. stock dividend payoutJuly 2025 Decliners & Real-Time Volume Analysis Alerts - BỘ NỘI VỤ
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):